Ikarian Capital, LLC Galectin Therapeutics Inc Transaction History
Ikarian Capital, LLC
- $573 Million
- Q3 2024
A detailed history of Ikarian Capital, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Ikarian Capital, LLC holds 500,000 shares of GALT stock, worth $1.16 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
500,000Holding current value
$1.16 Million% of portfolio
0.24%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding GALT
# of Institutions
91Shares Held
9.65MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$4.93 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$3.61 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$2.73 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$1.99 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.12 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $137M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...